Therapies for COVID-19 include use of human recombinant soluble ACE2 to act as decoy receptors for binding and neutralizing SARS-CoV-2 [99,100] and inhibition TMPRSS2 activity to prevent spike protein priming [101,102]. Here, ACE2 is linked to COVID-19.